Amphiregulin and epidermal hyperplasia: Amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice

American Journal of Pathology

Volumn 166, Issue 4, 2005, Pages 1009-1016

  Bhagavathula, Narasimharao ^a   Nerusu, Kamalakar C ^a   Fisher, Gary J ^b   Liu, Gao ^c   Thakur, Archana B ^c   Gemmell, Lorraine ^c   Kumar, Shankar ^c   Xu, Zenghai H ^c   Hinton, Paul ^c   Tsurushita, Naoya ^c   Landolfi, Nicholas F ^c   Voorhees, John J ^b   Varani, James ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c PROTEIN DESIGN LABS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; EPIDERMIS HYPERPLASIA; GENE OVEREXPRESSION; KERATINOCYTE; MONOLAYER CULTURE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSORIASIS; SCID MOUSE; SKIN FIBROBLAST; SKIN GRAFT; SKIN TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; THICKNESS;

EID: 20244382424     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62322-X     Document Type: Article

References (46)

1. Krueger GC, Bergstresser PR, Lowe NJ, Voorhees JJ, Weinstein GD: Psoriasis. J Am Acad Dermatol 1984, 11:937-947
2. Fry L: Psoriasis. Br J Dermatol 1988, 119:445-461
3. Sander HM, Morris LF, Phillips CM, Harrison PE, Menter A: The annual cost of psoriasis. J Am Acad Dermatol 1993, 128:422-425
4. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ: Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002, 47:512-518
5. Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L: Psoriasis: a T-cell mediated autoimmune disease mediated by streptococcal superantigen? Immunol Today 1995, 16:145-149
6. Austin LM, Ozawa M, Kikuchi T, Walters IB, Kueuger JG: The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines-interferon-γ, interleukin-2 and tumor necrosis factor-α-defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias also measured in circulating blood T cells in psoriasis patients. J Invest Dermatol 1999, 113:101-108
7. Baker BS, Brent L, Valdimarsson H, Powles AV, al-Imara L, Walker M, Fry L: Is epidermal proliferation in psoriatic skin grafts on nude mice driven by T-cell derived cytokines? Br J Dermatol 1992, 126:105-110
8. Wong RL, Winslow CM, Cooper KD: The mechanisms of action of cyclosporin A in the treatment of psoriasis. Immunol Today 1993, 14:69-74
9. Dustin ML, Singer KH, Tuck DT, Springer TA: Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon-gamma and is mediated by intercellular adhesion molecule-1. J Exp Med 1988, 167:1323-1340
10. Nickoloff BJ, Mitra RS, Elder JT, Fisher GJ, Voorhees JJ: Decreased growth inhibition by recombinant gamma interferon is associated with increased production of transforming growth factor alpha in keratinocytes cultured from psoriatic lesions. Br J Dermatol 1989, 121:161-174
11. Nickoloff BJ: The cytokine network in psoriasis. Arch Dermatol 1991, 127:871-884
12. Goebeler M, Toksoy A, Spandau U, Engelhardt E, Broker EB, Gillitzer R: The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998, 184:89-95
13. Varani J, Kang S, Stoll S, Elder JT: Human psoriatic skin in organ culture: comparison with normal skin exposed to exogenous growth factors and effects of an antibody to the EGF receptor. Pathobiology 1998, 66:253-259
14. Gottlieb AB, Chang CK, Posnett DN, Fanelli B, Tam JP: Detection of transforming growth factor-alpha in normal, malignant and hyperproliferative human keratinocytes. J Exp Med 1988, 167:670-675
15. Elder JT, Fisher GJ, Lindquist PB, Bennett GJ, Pittelkow MR, Coffey RJ, Ellingsworth L, Derynck R, Voorhees JJ: Overexpression of transforming growth factor-α in psoriatic epidermis. Science 1989, 243:811-814
16. Piepkorn M, Pittelkow MR, Cook PW: Autocrine regulation of keratinocytes: the emerging role of heparin-binding, epidermal growth factor-related growth factors. J Invest Dermatol 1998, 111:715-721
17. Piepkorn M, Predd H, Underwood R, Cook P: Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res 2003, 295:93-101
18. Cook PW, Pittelkow MR, Keeble WW, Graves-Deal R, Coffey Jr RJ, Shipley GD: Amphiregulin messenger RNA is elevated in psoriatic epidermis and gastrointestinal carcinomas. Cancer Res 1992, 52:3224-3227
19. Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR, Pittelkow MR: Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 1997, 100:2286-2294
20. Cook PW, Brown JR, Cornell KA, Pittelkow MR: Suprabasal expression of human amphiregulin in the epidermis of transgenic mice induces a severe, early-onset, psoriasis-like skin pathology: expression of amphiregulin in the basal epidermis is also associated with synovitis. Exp Dermatol 2004, 13:347-356
21. Palladino MA, Bahjat FR, Theodorakis EA, Moldawer LL: Anti-TNF-alpha therapies: the next generation. Nat Rev Drug Discov 2003, 2:736-746
22. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ, Shoyab M: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumor-inhibitory activity. Mol Cell Biol 1990, 10:1969-1981
23. Queen C, Schneider WP, Selick HE, Payne PW, Landolfi NF, Duncan JF, Avdalovic NM, Levitt M, Junghans RP, Waldmann TA: A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989, 186:10029-10033
24. Levitt M: Molecular dynamics of native protein. I. Computer simulation of trajectories. J Mol Biol 1983, 168:595-617
25. Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H, Magid P, Ehrlich P, Nadler PI, Ash RC: Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation 1991, 51:1190-1196
26. Zeigler M, Chi Y, Tumas DB, Bodary S, Tang H, Varani J: Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab Invest 2001, 81:1253-1261
27. Ellis CN, Varani J, Fisher GJ, Pershadsingh HA, Benson SC, Kurtz TW: Troglitazone improves psoriasis and normalizes models of proliferative skin disease. Arch Dermatol 2000, 136:609-615
28. Nickoloff BJ, Kunkel SL, Burdick M, Strieter RM: Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 1995, 146:580-588
29. Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996, 98:1878-1887
30. Gilhar A, David M, Ullmann Y, Berkutski T, Kalish RS: T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol 1997, 109:283-288
31. Dam TM, Kang S, Nickoloff BJ, Voorhees JJ: 1α25-dihydroxychole- calciferol and cyclosporin suppress induction and promote resolution of psoriasis in human skin grafts transplanted on to SCID mice. J Invest Dermatol 1999, 113:1082-1089
32. Varani J, Hattori Y, Chi Y, Schmidt T, Perone P, Zeigler ME, Fader DJ, Johnson TM: Collagenolytic and gelatinolytic matrix metalloproteinases and their inhibitors in basal cell carcinoma of skin: comparison with normal skin. Br J Cancer 2000, 82:657-665
33. Varani J, Perone P, Griffiths CEM, Inman D, Fligiel SEG, Voorhees JJ: All-trans retinoic acid stimulates events in organ-cultured skin that underlie repair. J Clin Invest 1994, 94:1747-1753
34. Pittelkow MR, Cook PW, Shipley GD, Derynck R, Coffey Jr RJ: Autonomous growth of human keratinocytes requires epidermal growth factor receptor occupancy. Cell Growth Differ 1993, 4:513-521
35. Cook PW, Mattox PA, Keeble WW, Pittelkow MR, Plowman GD, Shoyab M, Adelman JP, Shipley GD: A heparin sulfate-regulated human keratinocyte autocrine factor is similar or identical to amphiregulin. Mol Cell Biol 1991, 11:2547-2557
36. Cook PW, Pittelkow MP, Shipley GD: Growth factor-independent proliferation of normal human neonatal keratinocytes: production of autocrine and paracrine mitogenic factors. J Cell Physiol 1991, 146:277-289
37. Varani J, Warner RL, Mehrnaz G-K, Phan SH, Kang S, Chung JH, Wang ZQ, Datta SC, Fisher GJ, Voorhees JJ: Vitamin A antagonizes decreased cell growth and elevated collagen-degrading matrix metalloproteinases and stimulates collagen accumulation in naturally aged human skin. J Invest Dermatol 2000, 114:480-486
38. Piepkorn M: Overexpression of amphiregulin, a major autocrine growth factor for cultured human keratinocytes, in hyperproliferative skin diseases. Am J Dermatopathol 1996, 18:165-171
39. Zeigler ME, Chi Y, Schmidt T, Varani J: Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J Cell Physiol 1999, 180:271-284
40. Hobbs RM, Watt FM: Regulation of interleukin-1 alpha expression by integrins and epidermal growth factor receptor in keratinocytes from a mouse model of inflammatory skin disease. J Biol Chem 2003, 278:19798-19807
41. Mascia F, Mariani V, Girolomoni G, Pasture S: Blockade of the EGF receptor induces a deranged cytokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003, 163:303-312
42. Varani J, Zeigler M, Dame MK, Kang S, Fisher GJ, Voorhees JJ, Stoll SW, Elder JT: HB-EGF activation of keratinocyte ErbB receptors mediates epidermal hyperplasia, a prominent side effect of retinoid therapy. J Invest Dermatol 2001, 117:1335-1341
43. Tavakkol A, Varani J, Elder JT, Zouboulis CC: Maintenance of human skin in organ culture: role for insulin-like growth factor-1 receptor and epidermal growth factor receptor. Arch Dermatol Res 1999, 291:643-651
44. Greaves MW, Weinstein GD: Treatment of psoriasis. N Engl J Med 1995, 332:581-588
45. McKay IA, Winyard P, Leigh IM, Bustin SA: Nuclear transcription factors as potential targets for new modes of intervention in skin disease. Br J Dermatol 1994, 131:591-592
46. McMichael AJ, Griffiths CEM, Talwar HA, Finkel LJ, Rafal ES, Hamilton TA, Voorhees JJ: Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy. Br J Dermatol 1996, 135:60-64